✨ Key Finding: Higher aldosterone-renin ratio (ARR) was independently associated with increased risks of atrial fibrillation (aHR 1.10) and ischemic stroke (aHR 1.13) in older adults.
✨ Key Finding: Seven out of twelve heart failure guidelines met AGREE II criteria, showing broad consensus on management but significant variability in treatment recommendations.
Cohort study identifies low prevalence and poor management of genotype-positive familial hypercholesterolemia, highlighting implications for cardiovascular health.
Based on your interests and feeds
✨ Key Finding: The artificial intelligence model could reduce unnecessary invasive coronary angiographies by 27%, improving diagnostic efficiency and resource utilization.
✨ Key Finding: Alirocumab treatment resulted in a reduction in percentage atheroma volume (PAV) by 1.29% compared to a 1.25% reduction in the placebo group, showing comparable treatment effects for both segmentation methods (ED vs 1-mm analysis).

“ED- and 1-mm-based analyses demonstrated comparable treatment effects of alirocumab on plaque regression in PACMAN-AMI. The use of the 1-mm segmentation method should be preferred in serial IVUS studies. By Nathan Yap https://t.co/cxdiGD4mXn #circ_j #CardioX https://t.co/wdUxVVtpNq”
✨ Key Finding: Patients with chronic kidney disease at index heart failure hospitalisation have a 55% higher risk of death and nearly twice the healthcare costs compared to those without CKD.
✨ Key Finding: Intravenous tirofiban plus EVT aims to demonstrate noninferior efficacy compared to thrombolysis bridging with EVT in acute ischemic stroke patients.
✨ Key Finding: Guideline-concordant echocardiographic surveillance in adults with aortic stenosis is associated with improved outcomes and reduced mortality rates.
✨ Key Finding: SGLT2 inhibitors received a class IA recommendation for heart failure management, emphasizing their relevance due to the rising burden of heart failure in the Middle East and Africa.
✨ Key Finding: A combination of strategies, including educational initiatives and digital health tools, may enhance the implementation of guideline-recommended lipid-lowering therapies.